- Home
- PHIO vs BPTH Comparison
PHIO vs BPTH Comparison
Compare PHIO & BPTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHIO
- BPTH
- Stock Information
- Founded
- PHIO 2011
- BPTH 2007
- Country
- PHIO United States
- BPTH United States
- Employees
- PHIO N/A
- BPTH N/A
- Industry
- PHIO Biotechnology: Pharmaceutical Preparations
- BPTH Biotechnology: Pharmaceutical Preparations
- Sector
- PHIO Health Care
- BPTH Health Care
- Exchange
- PHIO Nasdaq
- BPTH Nasdaq
- Market Cap
- PHIO 3.4M
- BPTH 3.5M
- IPO Year
- PHIO N/A
- BPTH N/A
- Fundamental
- Price
- PHIO $2.77
- BPTH $0.82
- Analyst Decision
- PHIO Strong Buy
- BPTH Strong Buy
- Analyst Count
- PHIO 1
- BPTH 2
- Target Price
- PHIO $36.00
- BPTH $30.00
- AVG Volume (30 Days)
- PHIO 18.5M
- BPTH 6.3M
- Earning Date
- PHIO 11-14-2024
- BPTH 03-07-2025
- Dividend Yield
- PHIO N/A
- BPTH N/A
- EPS Growth
- PHIO N/A
- BPTH N/A
- EPS
- PHIO N/A
- BPTH N/A
- Revenue
- PHIO N/A
- BPTH N/A
- Revenue This Year
- PHIO N/A
- BPTH N/A
- Revenue Next Year
- PHIO N/A
- BPTH N/A
- P/E Ratio
- PHIO N/A
- BPTH N/A
- Revenue Growth
- PHIO N/A
- BPTH N/A
- 52 Week Low
- PHIO $1.53
- BPTH $0.59
- 52 Week High
- PHIO $10.35
- BPTH $10.00
- Technical
- Relative Strength Index (RSI)
- PHIO 50.99
- BPTH 42.72
- Support Level
- PHIO $2.41
- BPTH $0.69
- Resistance Level
- PHIO $4.53
- BPTH $1.22
- Average True Range (ATR)
- PHIO 0.83
- BPTH 0.13
- MACD
- PHIO 0.12
- BPTH -0.04
- Stochastic Oscillator
- PHIO 14.18
- BPTH 20.00
About PHIO Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.
About BPTH Bio-Path Holdings Inc.
Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. The other drugs of the company are BP1002, BP1003, BP1001-A, and DNABILIZE.